Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fractionated radiotherapy plus Toripalimab in high-/very-high-risk NMIBC
ChiCTR2200059970Phase 2Recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-muscle-invasive bladder cancer (NMIBC), sponsored by West China Hospital of Sichuan University. Primary endpoints: Disease-free survival and Safety. Started Feb 2023; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2200059970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059970.